Navigation Links
Former Head of UK Medicines & Healthcare Products Regulatory Agency (MHRA) Sir Alasdair Breckenridge Joins NDA Partners
Date:8/14/2013

Madison, VA (PRWEB) August 14, 2013

Carl Peck, MD, Chairman of NDA Partners LLC (NDAP), today announced that Sir Alasdair Breckenridge, former head of the UK Medicines & Healthcare Products Regulatory Agency (MHRA) has joined NDA Partners as a partner in the firm. MHRA is the Department of Health agency responsible for regulating all medicines and medical devices marketed in the UK.

In his role at NDA Partners, Sir Alasdair will provide leadership for the firm’s expanding EU operations and expert consulting to its worldwide client base in complex and rapidly evolving topics such as health care policy, health technology assessment, reimbursements, EU clinical trials, global product development, global regulatory strategies, benefit-risk assessment, and bioethics. “Alasdair’s decades of experience at the forefront of drug development science and deep understanding of the global regulatory environment will be a tremendous asset for our clients as they seek the best available advice to guide their development programs”, said Dr Peck. “We look forward to Alasdair’s active involvement on our team and with our global client base”.

Sir Alasdair has a long and prestigious career in drug development science and regulatory affairs. He was the first Chair of MHRA when it was formed in 2003 and retained this position until his retirement from the Agency in 2012. During his tenure at MHRA, he served as the first Chair of the Department of Health's Emerging Science and Bioethics Advisory Committee (ESBAC), an organization responsible for providing advice to UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. He was a member of the Medical Research Council, worked closely on several programs of the European Union, the World Health Organization and the International Union of Pharmacology, and was Chair of the Committee on Safety of Medicines. Prior to MHRA, he was Professor of Clinical Pharmacology at the University of Liverpool and a member and then Chairman of local and regional health authorities in the north-west of England, including Chairman of the North West Regional Office. Sir Alasdair is a clinical pharmacologist and after training at the Royal Postgraduate Medical School, he was appointed to the Chair of Clinical Pharmacology at the University of Liverpool. Sir Alasdair was knighted in 2004.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11018273.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
2. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PharmaVentures Helps Secure Investor for Former MSD Research Site
5. Dr. Michael Yaremchuk, Leading Performer of Custom-Designed Facial Implants, Pioneers Bespoke Plastic Surgery
6. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Prepare for FDA Inspections of Their Quality Systems
7. Ceres Expands Board of Directors with former BP Chief Scientist and Undersecretary of Energy Steven Koonin
8. Former Stryker CEO Takes Reins at sBioMed
9. Lucas Bagnell Varga LLC Secures $17.4 Million Award For Former Applied Biosystems Executives
10. Non-Intrusive Black Mold Removal Procedure Released By Former Mold Remediation Specialist, MyCleaningProducts.com Explains
11. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):